1-(2-Ethoxyethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole hydrochloride 99%

Mekanar Pharma is end-to-end contract research, development, and manufacturing organization (CRO-CDMO) offering products and services across the drug development spectrum to enable our partners to turn their concepts into commercials along with API development with a full range of developing our own analytical methods and protecting the process by filing patents.

We work with global pharma companies to accelerate the discovery, development and manufacture of complex small molecules, consistently delivering values based on quality, responsiveness, and transparency. Our development is tailor made and will be on a cost competitive edge wrt the API global prices.

Mekanar Pharma is established in 2022. We are young, dynamic and fast-growing Active Pharmaceutical Ingredient (API) company, headquartered in Hyderabad, India.

Our ability to offer end-to-end solutions and support standalone programs is derived from our experienced team, enabling technologies, and a partnership approach to every engagement. Our services offer a list of comprehensive programs from materials management and API sourcing to development, manufacturing, regulatory support, and packaging.